Shattuck Labs
STTKSTTK · Stock Price
Historical price data
Overview
Shattuck Labs is a clinical-stage biotech with a mission to establish DR3 blockade as a new standard of care in inflammatory and immune-mediated diseases. The company has rapidly advanced its lead asset, SL-325, into Phase 2 development for IBD, leveraging a differentiated receptor-blocking strategy to potentially overcome limitations of existing TL1A-targeting therapies. Its strategy hinges on demonstrating best-in-class remission rates and a favorable immunogenicity profile to capture significant market share in the competitive IBD landscape.
Technology Platform
Proprietary platform for engineering high-affinity, Fc-silenced monoclonal antibodies that target and block Death Receptor 3 (DR3), focusing on receptor blockade to avoid immune complex formation and reduce immunogenicity.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| SL-172154 + Azacitidine (AZA) + Venetoclax | Acute Myeloid Leukemia | Phase 1 | |
| Drug: SL-172154 | Cutaneous Squamous Cell Carcinoma | Phase 1 | |
| SL-279252 | Squamous Cell Carcinoma of the Head and Neck | Phase 1 | |
| SL-172154 | Ovarian Cancer | Phase 1 | |
| Pegylated Liposomal Doxorubicin + SL-172154 + Mirvetuximab +... | Platinum-resistant Ovarian Cancer | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Shattuck competes directly with Phase 3 TL1A ligand blockers (Merck, Sanofi, Roche) and established IBD therapies. Its differentiation hinges on the unproven clinical advantage of receptor blockade (DR3) over ligand blockade (TL1A), aiming for comparable efficacy with lower immunogenicity. It currently holds a first-mover advantage in the DR3 antagonist niche.
